# Extended Access of Momelotinib in Adults With Myelofibrosis

Source: https://onco.cc/trials/nct03441113/  
OnCo record `nct03441113` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of MMB in myeloproliferative neoplasms, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

Extended Access of Momelotinib in Adults With Myelofibrosis is a phase 2 interventional study registered as NCT03441113 by GlaxoSmithKline, with 237 participants enrolled, started 2018-05-03 and due to reach its primary completion in 2026-12-11. Interventions recorded: MMB.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03441113
- Phase: 2
- Setting: Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
- Sponsor: GlaxoSmithKline
- Enrolled: 237

## Sources

- ClinicalTrials.gov NCT03441113: https://clinicaltrials.gov/study/NCT03441113

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct03441113.json